Advanced search
Publication Cover
Future Oncology Volume 12, 2016 - Issue 16
Submit an article Journal homepage
1,295
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Is It Time for Everolimus-Based Combination in Castration-Resistant Prostate Cancer?

Giandomenico Roviello1 Section of Pharmacology & University Center DIFF – Drug Innovation Forward Future, Department of Molecular & Translational Medicine, University of Brescia, Viale Europa 11, 25124Brescia, Italy;2 Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100Cremona, ItalyCorrespondence[email protected]
,
Andrea Ravelli2 Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100Cremona, Italy;3 Section of Experimental Oncology, Department of Clinical & Experimental Medicine, University of Parma, Via Università, 12, 43121Parma, Italy
,
Sandro Barni4 Unit of Oncology, Azienda Ospedaliera Treviglio, Treviglio(BG), Italy
,
Fausto Petrelli4 Unit of Oncology, Azienda Ospedaliera Treviglio, Treviglio(BG), Italy
,
Alberto Bottini2 Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100Cremona, Italy
,
Stephen B Fox5 Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia;6 Department of Pathology, University of Melbourne, Melbourne, Australia
&
Daniele Generali2 Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100Cremona, Italy;7 Department of Medical, Surgery & Health Sciences, Università degli Studi di Trieste, Trieste, Italy
 show all
Pages 1849-1852 | Received 22 Mar 2016, Accepted 20 Apr 2016, Published online: 02 Jun 2016

References

  • Attard G , ParkerC, EelesRAet al. Prostate cancer. Lancet387(10013), 70–82 (2016).
  • Massard C , FizaziK. Targeting continued androgen receptor signaling in prostate cancer. Clin. Cancer Res.17, 3876–3883 (2011).
  • Roviello G , PetrioliR, LaeraL, FranciniE. The third line of treatment for metastatic prostate cancer patients: option or strategy?Crit. Rev. Oncol. Hematol.95(3), 265–271 (2015).
  • Titus MA , SchellMJ, LihFBet al. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin. Cancer Res.11, 4653–4657 (2005).
  • Dillard PR , LinMF, KhanSA. Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol. Cell Endocrinol.295, 115–120 (2008).
  • Antonarakis ES , LuC, WangHet al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl. J. Med.371(11), 1028–1038 (2014).
  • Hu R , LuC, MostaghelEAet al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res.72, 3457–3462 (2012).
  • Nakazawa M , LuC, ChenYet al. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann. Oncol.26(9), 1859–1865 (2015).
  • Thadani-Mulero M , PortellaL, SunSet al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res.74(8), 2270–2282 (2014).
  • Onstenk W , SieuwertsAM, KraanJet al. Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells. Eur. Urol.68(6), 939–945 (2015).
  • Debes JD , TindallDJ. Mechanisms of androgen-refractory prostate cancer. N. Engl. J. Med.351, 1488–1490 (2004).
  • Carver BS , ChapinskiC, WongvipatJet al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell19, 575–586 (2011).
  • Nan B , SnabboonT, UnniE, YuanXJ, WhangYE, MarcelliM. The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity. J. Mol. Endocrinol.31, 169–183 (2003).
  • McMenamin ME , SoungP, PereraS, KaplanI, LodaM, SellersWR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res.59(17), 4291–4296 (1999).
  • Kato M , BanuelosCA, ImamuraYet al. Cotargeting androgen receptor splice variants and mTOR signaling pathway for the treatment of castration-resistant prostate cancer. Clin Cancer Res. doi: 10.1158/1078-0432.CCR-15-2119 (2016) ( Epub ahead of print).
  • Kaarbo M , MikkelsenOL, MalerodL, QuS, LobertVH, AkgulG. PI3K–AKT–mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells. Cell Oncol.32, 11–27 (2010).
  • Ferraldeschi R , Nava RodriguesD, RiisnaesRet al. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur. Urol.67(4), 795–802 (2015).
  • Nakabayashi M , WernerL, CourtneyKDet al. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int.110, 1729–1735 (2012).
  • Templeton AJ , DutoitV, CathomasRet al. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur. Urol.64(1), 150–158 (2013).
  • Baselga J , CamponeM, PiccartMet al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med.366(6), 520–529 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.